ArticleInsights into imaging2011
Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR).
Article in Insights into imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Evaluation of background parenchymal enhancement on breast MRI: a systematic review.The British journal of radiology · 2017Pooled it
- Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014.American journal of respiratory and critical care medicine · 2015Pooled it
- Role of molecular imaging in prognosis, diagnosis, and treatment of gastrointestinal cancers: An update on new therapeutic methods.World journal of methodology · 2024Review
- Magnetic Resonance-Guided Cancer Therapy Radiomics and Machine Learning Models for Response Prediction.Tomography (Ann Arbor, Mich.) · 2024Review
- Nanoparticles in Cancer Diagnosis and Treatment.Materials (Basel, Switzerland) · 2023Review
- Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives.Biomarker research · 2023Review
- Autonomous service for managing real time notification in detection of COVID-19 virus.Computers & electrical engineering : an international journal · 2022Article
- Unique Properties of Surface-Functionalized Nanoparticles for Bio-Application: Functionalization Mechanisms and Importance in Application.Nanomaterials (Basel, Switzerland) · 2022Review
- Magnetic Nanoparticles in Cancer Therapy and Diagnosis.Advanced healthcare materials · 2020Review
- Monoclonal antibody-based molecular imaging strategies and theranostic opportunities.Theranostics · 2020Review
- Strategic research agenda for biomedical imaging.Insights into imaging · 2019Article
- Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models.Contrast media & molecular imaging · 2019Review
- Machine learning: from radiomics to discovery and routine.Der Radiologe · 2018Article
- Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study.PLoS medicine · 2018Article
- The crucial role of multiomic approach in cancer research and clinically relevant outcomes.The EPMA journal · 2018Review
- The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment.EBioMedicine · 2018Review
- Nano-Magnetic Resonance Imaging (Nano-MRI) Gives Personalized Medicine a New Perspective.Biomedicines · 2017Article
- ESR Position Paper on Imaging Biobanks.Insights into imaging · 2015Article
- The ESR Patient Advisory Group (ESR-PAG).Insights into imaging · 2015Article
- Biomarkers in preclinical cancer imaging.European journal of nuclear medicine and molecular imaging · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The future of medicine lies in early diagnosis and individually tailored treatments, a concept that has been designated 'personalised medicine' (PM), i.e. delivering the right treatment to the right patient at the right time. However, the value of medical imaging in PM is frequently underestimated, as many policy makers forget the all-important right location in the PM paradigm. Medical imaging has always been personalised as it provides individual assessment of the location and extent of an abnormality, and in the future it will prove fundamental to almost all aspects of PM. Stratification based on imaging biomarkers can help identify individuals suited for preventive intervention and can improve disease staging. In vivo visualisation of locoregional physiological, biochemical and biological processes using molecular imaging can detect diseases in pre-symptomatic phases or facilitate individualised drug delivery. Furthermore, imaging is essential to patient-tailored therapy planning, therapy monitoring and follow-up of disease progression, as well as targeting non-invasive or minimally invasive treatments, especially with the rise of theranostics. For PM to reach its full potential, medical imaging must be an integral part. Radiologists need to be prepared for this new paradigm as it will mean changes in training, in research and in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.